REYATAZ

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, France, Hong Kong SAR China, Ireland, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, UK.

Active ingredients

The drug REYATAZ contains one active pharmaceutical ingredient (API):

1	Atazanavir UNII 4MT4VIE29P - ATAZANAVIR SULFATE
	Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.
	Read more about Atazanavir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REYATAZ Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AE08	Atazanavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10321F, 10349Q
BR	Câmara de Regulação do Mercado de Medicamentos	505107902111212, 505107903116315
CA	Health Products and Food Branch	02248610, 02248611, 02294176
EE	Ravimiamet	1208168, 1208179, 1208180, 1208191, 1368086, 1402489, 1722495, 1722507
ES	Centro de información online de medicamentos de la AEMPS	03267004, 03267006, 03267008
FR	Base de données publique des médicaments	66745660, 68301348, 69443966
GB	Medicines & Healthcare Products Regulatory Agency	136417, 73374, 73377
HK	Department of Health Drug Office	52846, 56784
IT	Agenzia del Farmaco	036196018, 036196020, 036196032, 036196044, 036196057, 036196069, 036196071, 036196083, 036196095, 036196107, 036196119, 036196121
JP	医薬品医療機器総合機構	6250023M1026, 6250023M2022
LT	Valstybinė vaistų kontrolės tarnyba	1030704, 1030705, 1030706, 1030707, 1030708, 1030709, 1032112, 1032113, 1056564, 1080849, 1080850
NL	Z-Index G-Standaard, PRK	74330, 74349, 86479
NZ	Medicines and Medical Devices Safety Authority	11007, 11008, 13160
PL	Rejestru Produktów Leczniczych	100125810, 100125827, 100125833, 100193409, 100398726
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65567001, W65567002, W65568001, W65568002, W65569001, W65569002, W65569003
SG	Health Sciences Authority	12520P, 12521P, 13560P
US	FDA, National Drug Code	0003-3622, 0003-3624, 0003-3631, 0003-3638, 67296-1236
ZA	Health Products Regulatory Authority	A39/20.2.8/0088, A39/20.2.8/0089